Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice

Klein, Richard J.T.; Buimovici‐Klein, Elena; Moser, Hans; Moucha, R; Hilfenhaus, J.

doi:10.1007/bf01314437

Cited by 32 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have recently demonstrated that the vaccine utilized in the present study elicited both humoral and CMI in mice, rabbits and chimpanzees (1, 2, 3) and these observations are also in agreement with others who found similar results after vaccination with subunits vaccine or envelope proteins (5,6).…”

Section: Diseussionsupporting

confidence: 94%

Immune response to a DNA free herpes simplex vaccine in man

Cappel¹,

Sprecher²,

Rickaert³

et al. 1982

Archives of Virology

View full text Add to dashboard Cite

A DNA-free subunit herpes simplex virus (HSV) vaccine was administered to 15 volunteers without past evidence of HSV infection and to 25 patients with severe recurrent HSV infection. The immune response to the vaccine in these patients was compared to the immunological status of 20 non-vaccinated control patients with recurrent HSV infection. The vaccine elicited antibody and cell-mediated immunity (CMI) in the 15 subjects without past evidence of HSV infection and this response was similar to that observed after a natural infection. Among the 25 patients who were suffering from recurrent HSV infection the vaccine elicited complement dependent cytotoxic antibodies in 13 of these patients who did not possess these antibodies and increased significantly the titers of these antibodies in the 12 other patients. The vaccine gave a significant increase of the titers of the other specific antibodies as well as the level of cell-mediated immunity. The increase of the immunity level in these latter patient was not due to normal variations since in the non-vaccinated control group the antibody titers and CMI remained stable during the same period of time.

show abstract

Section: Diseussionsupporting

confidence: 94%

Immune response to a DNA free herpes simplex vaccine in man

Cappel¹,

Sprecher²,

Rickaert³

et al. 1982

Archives of Virology

View full text Add to dashboard Cite

show abstract

“…[Cappel et al, 1978;Cappel et al, 1980;Cappel et al, 19821 as well as in humans [Cappel et al, 1980;Cappel et al, 19821. These observations are also in agreement with others who found similar results after immunization with slightly different subunit vaccines, envelope proteins, or purified glycoproteins [Balachandra et al, 1982;Hilleman et al, 1981;Kitces et al, 1977;Klein et al, 1981;Skinner et al, 19821. In the various animal models studied, we and others reported earlier that these vaccines protected the animals against experimental infection [Capel, 1976;Hilleman et al, 1981;Kitces et al, 19771. In the present study we confirmed that the vaccine elicited the production of various types of specific antibodies as well as CMI in humans.…”

Section: Discussionsupporting

confidence: 93%

Clinical efficacy of a herpes simplex subunit vaccine

Cappel¹,

Sprecher²,

Cuyper³

et al. 1985

Journal of Medical Virology

View full text Add to dashboard Cite

A DNA-free herpes simplex type 2 subunit vaccine was administered to 18 volunteers without past evidence of herpes simplex type 1 (HSV 1) or herpes simplex type 2 (HSV 2) infection, to 44 patients with severe recurrent genital HSV 2 infection, and to 15 patients with severe oral type 1 HSV recurrences. The vaccine elicited both humoral and cell-mediated immunity in 97% of the subjects without past HSV infections and boosted significantly the cell-mediated immunity and antibody titers in almost all the patients with recurrent HSV 1 or HSV 2. The vaccine elicited particularly the production of complement-dependent cytotoxic antibodies in 96% of the patients with recurrent HSV 2 infections. This might, at least partly, explain the clinical efficacy of the vaccine. Indeed, we observed a significant decrease (t test, p less than 0.01) in the attack rate of the recurrences and also a significant shortening of the time needed to complete healing of the lesions (t test, p less than 0.01).

show abstract

“…Stanberry and co-workers [28] reported that both the number of episodes of recurrent disease seen following intravaginal HSV-2 infection of guinea-pigs and their duration, were significantly reduced in animals previously given a mixture of HSV-1 gB and gD with Freund's Complete Adjuvant, compared to control, unimmunized animals. Other workers have reported that subunit HSV vaccines or purified HSV glycoproteins have failed to provide any significant protection against the establishment of latent infection in mice [6,9,19] although injection of one preparation in the presence of the adjuvant polyriboinosinic: polyribocytidylic acid-poly (L-lysine) and carboxymethylcellulose (PICLC) reduced the development of ganglionic infection [29].…”

Section: Discussionmentioning

confidence: 99%

Latent HSV-1 infection in mice immunized with a zwitterionic detergent-extracted HSV-1 antigen preparation

Alghamdi

Jennings

Bentley

et al. 1989

Archives of Virology

View full text Add to dashboard Cite

A HSV-1 antigen preparation obtained by zwitterionic detergent-extraction of HSV-1 infected Vero cells was investigated for its ability to protect mice against establishment of latent infection in the trigeminal ganglion following HSV-1 challenge by ear scarification. The antigen preparation was shown to induce antibody production and correlation between pre-challenge antibody level and establishment of latency was found. Although immunization did not reduce the overall incidence of ear erythema following challenge the duration of erythema was significantly decreased. Latency in the trigeminal ganglion was also significantly reduced in vaccinated mice and in addition, a correlation was found between the duration of erythema and latency, there being significantly more latent infections in mice with erythema of three or more days duration, than in those with erythema lasting less than three days.

show abstract

Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice

Cited by 32 publications

References 14 publications

Immune response to a DNA free herpes simplex vaccine in man

Immune response to a DNA free herpes simplex vaccine in man

Clinical efficacy of a herpes simplex subunit vaccine

Latent HSV-1 infection in mice immunized with a zwitterionic detergent-extracted HSV-1 antigen preparation

Contact Info

Product

Resources

About